Skip to main content
TipRanks
Go Ultimate75% OFF

Sinopharm Group Co (X2S1) AI Stock Analysis

1 Followers
DE:X2S1

Sinopharm Group Co

(Frankfurt:X2S1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Nationwide healthcare distribution networkThe nationwide distribution network gives Sinopharm broad access to institutional and retail healthcare customers. Its coverage across hospitals, clinics, pharmacies and providers supports recurring product flow and creates a durable platform for distributing medicines, devices and consumables at scale.
Negative Factors
Recent revenue contractionRecent revenue contraction marks a deterioration from the stronger growth seen during 2021–2023. If weaker sales persist, the company may have less operating leverage and reduced capacity to absorb distribution costs, while slower volume growth could limit improvement in earnings over the next several quarters.

Sinopharm Group Co (X2S1) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%DE:X2S1-13.76%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 6.66B
Dividend Yield
4.55%
Average Volume (3M)
80
Price to Earnings (P/E)
6.3
Beta (1Y)
0.33
Revenue Growth
-4.46%
EPS Growth
0.14%
Country
Germany
Employees
94,910
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Sinopharm Group Co Business Overview & Revenue Model

Company Description

Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharma...

Sinopharm Group Co Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:X2S1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CAHCAH73Outperform$64.97B36.18-62.56%0.73%10.00%16.74%
HSICHSIC65Neutral$9.53B23.3613.13%―6.15%15.68%
CORCOR64Neutral$68.51B19.96115.76%0.69%5.00%124.34%
MCKMCK64Neutral$127.33B28.24-161.18%0.31%8.19%21.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
YIYI33Underperform$24.95M-1.5923.64%―-23.90%-45.45%

* Healthcare Sector Average

Performance Comparison

0%50%100%DE:X2S1CORCAHHSICMCKYIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:X2S1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:X2S1Sinopharm Group Co., Ltd. Unsponsored ADR Class H9.55-1.81-15.95%
CORCencora, Inc.359.03-3.12-0.86%
CAHCardinal Health281.1076.8537.63%
HSICHenry Schein86.2214.9721.01%
MCKMcKesson Corporation1102.81250.9329.46%
YI111, Inc.2.84-1.06-27.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.